PCOS phenotype, features define risk for adverse obstetric outcomes
MedWire News: The risk for adverse obstetric or neonatal outcomes seen in women with polycystic ovary syndrome (PCOS) varies according to the different disease phenotypes and features, say Italian researchers.
Stefano Palomba (University Magna Graecia of Catanzaro) and colleagues performed clinical, biochemical, and ultrasonographic evaluations on 93 pregnant women with PCOS and 69 healthy pregnant women (controls).
Women with PCOS had a significantly higher cumulative rate of adverse obstetric or neonatal outcomes compared with controls, at 39.8 versus 11.6 percent (relative risk [RR] = 1.7), respectively.
The risk for adverse outcomes varied according to whether women had an ovulatory or oligoanovulatory phenotype, at RRs of 0.48 and 1.57, respectively.
When the team further categorized patients with PCOS, they found significant differences in the risk for adverse obstetric or neonatal outcomes, with RRs of 2.23, 1.93, 0.54, and 0.48 for non-polycystic ovaries (PCO), full-blown, non-hyperandrogenic, and ovulatory phenotypes, respectively.
The authors then looked at individual PCOS features and found that the presence of oligoamenorrhea and biochemical hyperandrogenism increased the risk for obstetric or neonatal complications 5.73- and 4.04-fold, respectively, compared with controls. No significant effect was seen for clinical hyperandrogenism and PCO.
The researchers call for further studies in a bigger sample population to confirm their findings.
MedWire (www.medwire-news.md) is an independent clinical news service provided by Current Medicine Group, a trading division of Springer Healthcare Limited. © Springer Healthcare Ltd; 2010
By Ingrid Grasmo